Targets and strategies for T-cell based vaccines in patients with B-cell chronic lymphocytic leukemia.
T-cell based immunotherapies might be a novel option for the treatment of B-cell chronic lymphocytic leukemia (B-CLL), a disease characterized by a prolonged natural course. Different strategies of active immunotherapy have been tested in vitro to enhance a specific T-cell response against tumor cells and an anti-leukemic effect has been observed in B-CLL patients after allogenic stem cell transplantation. Several antigens have been characterized as tumor/leukemia associated antigens (T/LAAs) in B-CLL with the potential to elicit specific anti-tumor response encompassing idiotype immunoglobulin, oncofetal antigen-immature laminin receptor protein (OFAiLRP), survivin, as well as fibromodulin, the receptor for hyaluronic acid mediated motility (RHAMM/CD168) and the murine double-minute 2 oncoprotein (MDM2). This study presents an overview of possible targets and genetherapeutical maneuvers for future immunotherapies of B-CLL patients and summarizes recent clinical vaccination trials with dendritic cells (DCs) for B-CLL.
Giannopoulos
Krzysztof
K
Department of Internal Medicine III, University of Ulm, Ulm, Germany.
Schmitt
Michael
M
D000818:Animals; D000951:Antigens, Neoplasm / Q000737:chemistry / Q000378:metabolism; D019496:Cancer Vaccines; D003713:Dendritic Cells / Q000166:cytology; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D007694:Killer Cells, Natural / Q000378:metabolism; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000517:prevention & control* / Q000628:therapy*; D008954:Models, Biological; D009000:Monocytes / Q000378:metabolism; D013601:T-Lymphocytes / Q000378:metabolism*
D000951:Antigens, Neoplasm; D019496:Cancer Vaccines